Physician profile
Ali A Saab
NPI 1932341294
$2,796.20
in general payments reported to CMS, 2019-2025
32 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $427 · 2021: $698 · 2022: $287 · 2023: $690 · 2024: $421 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $990.14 | 2020-2025 | |
| Chiesi USA, INC. | $199.97 | 2021-2023 | Kengreal |
| Kiniksa Pharmaceuticals, LTD. | $191.38 | 2021-2023 | Arcalyst |
| Bard Peripheral Vascular, INC. | $178.83 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $133.58 | 2022-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $121.39 | 2023-2025 | Verquvo |
| Pfizer INC. | $95.24 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $75.83 | 2022-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.68 | 2020-2024 | Lifevest |
| Bardy Diagnostics, INC. | $64.05 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $63.25 | 2024 | Arcalyst |
| Baxter Healthcare | $60.79 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $59.59 | 2020-2021 | |
| Philips North America LLC | $52.86 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.20 | 2021-2024 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $44.85 | 2020-2022 | |
| Medtronic, INC. | $40.28 | 2021-2023 | Micra |
| Edwards Lifesciences Corporation | $31.94 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Scpharmaceuticals INC. | $30.31 | 2025 | |
| Esperion Therapeutics, INC. | $30.29 | 2020-2024 | Nexletol |
| Abbott Laboratories | $24.81 | 2022 | |
| Medtronic Vascular, INC. | $24.30 | 2019-2020 | |
| Lundbeck LLC | $23.95 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.38 | 2023 | |
| Glaxosmithkline, LLC. | $18.10 | 2025 | Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $17.67 | 2021 | |
| Tactile Systems Technology INC | $15.51 | 2024 | Entre Plus, Flexitouch Plus |
| Novo Nordisk INC | $15.23 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.50 | 2023 | Wainua |
| Daiichi Sankyo INC. | $14.12 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.24 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $11.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Saab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.